Silence Therapeutics plc (OTCMKTS:SLNCF) Short Interest Up 351.9% in August

Silence Therapeutics plc (OTCMKTS:SLNCF) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,350 shares, an increase of 351.9% from the August 15th total of 520 shares. Based on an average trading volume of 521 shares, the short-interest ratio is presently 4.5 days.

Silence Therapeutics Stock Performance

Shares of Silence Therapeutics stock opened at $4.00 on Friday. Silence Therapeutics has a twelve month low of $1.06 and a twelve month high of $5.99. The business has a 50-day moving average price of $3.00 and a 200-day moving average price of $2.26.

Silence Therapeutics Company Profile

Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.

The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.